[Carcinoma in situ in bladder and urethra among renal transplanted patient: failure of BCG therapy].
We report the case of a 67-year-old patient, renal transplanted for two years, taken care for carcinoma in situ in bladder and urethra, and treated by intravesical instillations with bacillus Calmette-Guerin (BCG). After failure of a first treatment by Amétycine, a treatment by BCG is instituted during nine weeks. Two months after the end of the treatment, the patient died after bone and liver metastatic invasion of urothelial carcinoma. Management of urothelial high-risk tumour among renal transplanted patient is not clear. Despite successful treatments of few patients reported in literature, this failure called the question of the effectiveness of the BCG therapy in renal transplant patient and suggested an earlier attempt at diagnosis with systematic detection and aggressive therapeutic among these immunodepressed patients.
Tillou
X
X
Service d'urologie et transplantation, CHU hôpital Sud, avenue Laennec, 80054 Salouel, Amiens, France. xavtillou@hotmail.com
Raynal
G
G
Limani
K
K
Saint
F
F
Petit
J
J
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000368:Aged; D001500:BCG Vaccine / Q000627:therapeutic use*; D002278:Carcinoma in Situ / Q000188:drug therapy*; D017809:Fatal Outcome; D006801:Humans; D016030:Kidney Transplantation; D008297:Male; D009378:Neoplasms, Multiple Primary / Q000188:drug therapy*; D011183:Postoperative Complications / Q000188:drug therapy*; D017211:Treatment Failure; D014523:Urethral Neoplasms / Q000188:drug therapy*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
D000276:Adjuvants, Immunologic; D001500:BCG Vaccine